CELLECTIS - ADR (CLLS) Stock Analyst Ratings
NASDAQ:CLLS - Nasdaq - US15117K1034 - ADR - Currency: USD
ChartMill assigns a Buy % Consensus number of 86% to CLLS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 5.61. This target is 274.23% above the current price.
CLLS was analyzed by 13 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about CLLS.
In the previous month the buy percentage consensus was at a similar level.
CLLS was analyzed by 13 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-11-05 | Barclays | Maintains | Overweight -> Overweight |
| 2024-06-12 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-05-31 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023-11-01 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023-08-08 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2023-08-07 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2023-04-05 | Citigroup | Maintains | Buy |
| 2023-03-13 | JMP Securities | Reiterate | Market Outperform |
| 2023-03-13 | Oppenheimer | Maintains | Outperform |
| 2023-01-19 | JMP Securities | Maintains | Market Outperform |
| 2022-05-24 | Goldman Sachs | Maintains | Sell |
| 2022-05-18 | Baird | Upgrade | Neutral -> Outperform |
| 2022-05-13 | Barclays | Maintains | Overweight |
| 2022-01-06 | Wells Fargo | Downgrade | Overweight -> Equal-Weight |
| 2021-11-30 | JMP Securities | Initiate | Market Outperform |
| 2021-10-08 | Baird | Downgrade | Outperform -> Neutral |